Please make a donation to the Aplastic Anemia and MDS International Foundation this holiday season.
Dr. Gustavo Rivero describes strategies for the management of Low-Risk MDS, or Myelodysplastic Syndromes. He details supportive care for these patients, including transfusions and iron overload therapies.
Dr Vu Duong explains risk classifications for MDS. He dives into IPSS and IPSS-R scores, focused on helping patients to understand the meanings of high-risk and low-risk MDS.
Dr. Tiffany Tanaka from the University of California, San Diego explains the development of High-Risk MDS into AML. She talks about new diagnostic and treatment regimens for these patients.
Dr. Oved completed scientific and clinical training that included tenures as a Fulbright Fellow with the Weizmann Institute in Israel, the NYU School of Medicine with two years as a Howard Hughes Medical Fellow, followed by a residency in Pediatrics at NYP Weill Cornell Medical College. During his residency, he developed an interest in more translational questions working with Dr.
Eliot's disease of Myelodysplastic Syndromes with IDH1 and IDH2 mutations developed quickly. His son was his donor for the haploidentical bone marrow transplant, and now he thrives thanks to a clinical trial drug that keeps the Acute Myeloid Leukemia and MDS in remission. Listen to his story now.
Dr. Ehab Atallah discusses the good news about treatment for MDS, Myelodysplastic Syndromes, for patients ages 65 and older.
Terri shares the journey of Thomas' surprise diagnosis, rigorous treatment, and wonderful survivorship in this conversation.
10 years after diagnosis, Leigh Ann needed a bone marrow transplant. Five years later, her son did, too! Listen to her story of different family members having the same rare disease, Myelodysplastic Syndromes, here.
Veronica learned that delaying treatment was not a good idea.
That delay nearly ended her life.